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METHODOLOGY
Development of a multiplex real-time 
PCR assay for detection of Mycoplasma 
pneumoniae, Chlamydia pneumoniae 
and mutations associated with macrolide 
resistance in Mycoplasma pneumoniae 
from respiratory clinical specimens
Maaret Nummi, Laura Mannonen* and Mirja Puolakkainen
Abstract 
The aim of this study was to improve detection of Mycoplasma pneumoniae and Chlamydia pneumoniae in clinical 
specimens by developing a multiplex real-time PCR assay that includes identification of macrolide-resistant M. pneu-
moniae. Novel assays targeting a M. pneumoniae conserved hypothetical protein gene, M. pneumoniae 23S rRNA gene 
mutations associated with macrolide resistance and human β-globin gene (an endogenous internal control) were 
designed and combined with a previously published C. pneumoniae PCR targeting ompA gene. The resulting quadra-
plex PCR was validated with a panel of clinical specimens supplemented with external quality assessment specimens, 
simulated specimens and various bacterial and viral strains. The obtained results were compared to those obtained 
by reference PCRs or confirmed by sequencing (typing of macrolide resistance). The novel multiplex PCR assay was 
in 100 % agreement with reference PCRs. Four M. pneumoniae strains with macrolide resistance-associated mutations 
were identified among 42 strains, which comprises 9.5 % of the study material. Amplification of an internal control 
excluded sample-derived inhibition possibly leading to false-negative reporting. In conclusion, we have developed 
a resources conserving multiplex real-time PCR assay for simultaneous detection of M. pneumoniae, C. pneumoniae 
and the most common mutations leading to macrolide resistance in M. pneumoniae. The assay is a widely useful tool 
for detection of these respiratory pathogens and will also shed light on the occurrence of macrolide resistance in M. 
pneumoniae.
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Background
Mycoplasma pneumoniae and Chlamydia pneumoniae 
are common respiratory pathogens causing approxi-
mately 10–30 % and 5–10 %, respectively, of community 
acquired pneumonias (Atkinson et  al. 2008; Kuo et  al. 
1995). M. pneumoniae infections can also present with 
extrapulmonary symptoms, including mucocutaneous 
and central nervous system manifestations (Atkinson 
et al. 2008), and the clinical spectrum of C. pneumoniae 
infection includes reactive arthritis, worsening of asthma 
and cardiovascular disease (Orrskog et al. 2013).
Mycoplasma pneumoniae infection can occur in all age 
groups, but the severity of the disease tends to increase 
with the age of the patient. For immunocompromised 
patients, M. pneumoniae infection can lead to a severe 
pneumonia (Waites and Talkington 2004). C. pneumo-
niae IgG antibody prevalence bounces between 5 and 
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15  years of age and then increases steadily suggesting 
that most primary infections take place in school-age 
children and repeated infections occur later in life. Anti-
microbial therapy is available for M. pneumoniae and 
C. pneumoniae infection. In case antimicrobial treat-
ment is indicated, specific and rapid laboratory diag-
nosis is important as the diagnosis cannot be based on 
clinical symptoms only. M. pneumoniae pneumonias are 
often treated with macrolides but also tetracyclines and 
fluoroquinolones are effective (Waites and Talkington 
2004). Macrolides are often used for treatment due to 
their safety especially for children and pregnant women. 
However, in the last few years macrolide-resistant M. 
pneumoniae strains have emerged, with high rates in 
China and Japan, and lower rates in Europe and Canada 
(Principi and Esposito 2013). Resistance to macrolides 
is caused by point mutations in the bacterial 23S rRNA 
gene which reduces the affinity of the antibiotic for the 
ribosomes (Wolff et  al. 2008). The most common point 
mutations leading to the resistance are located in the 23S 
rRNA gene at positions 2063 and 2064, and include tran-
sition A to G or C (Waites and Talkington 2004; Lucier 
et al. 1995).
In recent years, nucleic acid-based assays targeting M. 
pneumoniae and C. pneumoniae have been developed 
(Dumke and Jacobs 2009, 2014; Winchell et  al. 2008). 
PCR-based methods have high sensitivity, short turna-
round time and the testing can be completed in a sin-
gle working day. Moreover, simultaneous amplification 
of more than one target in the same reaction (multiplex 
PCR) is becoming a rapid, economical and convenient 
means in a diagnostic laboratory to detect multiple path-
ogens causing similar symptoms and their genetic prop-
erties at the same. A variety of multiplex PCRs have been 
developed for detection of M. pneumoniae and C. pneu-
moniae (Thurman et  al. 2011; Welti et  al. 2003; Gullsby 
et  al. 2008; Miyashita et  al. 2004; McDonough et  al. 
2005). However, also molecular diagnosis has limitations 
since the mere presence of nucleic acid can denote either 
acute infection, persistence of nucleic acid after infection 
or asymptomatic carriage.
The aim of this study was to improve detection of M. 
pneumoniae and C. pneumoniae in clinical specimens 
by developing a time-saving and inexpensive multiplex 
real-time PCR assay for detection of C. pneumoniae, 
M. pneumoniae and the most common mutations in 
the M. pneumoniae 23S rRNA gene leading to resist-
ance for macrolide antibiotics. To our knowledge, this 
is the first report of a multiplex real-time PCR assay 
that in addition to the detection of M. pneumoniae, C. 
pneumoniae and internal control includes detection 
of macrolide resistance-associated mutations in M. 
pneumoniae.
Results
Sensitivity of co‑amplification
To assess the sensitivity of co-amplification of C. pneumo-
niae, M. pneumoniae and human beta-globin by multiplex 
real-time PCR, a range of concentrations of M. pneumo-
niae M129 and C. pneumoniae K-6 DNA were co-ampli-
fied. In addition, low concentrations of M. pneumoniae and 
C. pneumoniae were amplified in presence of high con-
centration of human DNA. Crossing threshold (Ct) values 
remained unchanged for the DNA that was in a lower con-
centration even when a high concentration of DNA from 
another organism was co-amplified (data not shown).
Internal control (IC) human beta‑globin
The human β-globin was co-amplified in the multiplex 
reaction as IC. Neither sample matrix-derived inhi-
bition in the PCR reaction, nor specimen processing 
errors potentially leading to false negative reporting 
were observed in this study. The Ct values in nose and/
or throat swabs (n =  72) varied between 18.9 and 28.1 
(mean 23.2, median 23) and for BALs (n  =  13) the Ct 
range was 21.6–29.6 (mean 25.3, median 26).
Analytical sensitivity
The analytical sensitivity, the limit of detection (LOD) 
with 95  % probability, was determined for M. pneumo-
niae and C. pneumoniae components of the multiplex 
real-time PCR using Probit analysis of the Validation 
Manager software (Finbiosoft, Espoo, Finland). The ana-
lytical sensitivity for M. pneumoniae was 2.9 copies/PCR-
reaction and for C. pneumoniae (K-6) the LOD was 0.13 
IFU/PCR reaction. To confirm that the C. pneumoniae 
primers and probe are able to detect different strains, 
DNA from nine available C. pneumoniae isolates were 
tested: The strains isolated in Finland K6, K8, K66, FIL, 
HELS-12, MS and Parola, CV6 from Germany (a kind 
gift from Prof. M Maass), and TW-183 (ATCC VR-2282) 
and CWL-029 (ATCC VR-1310). The multiplex PCR 
detected these strains.
Analytical specificity
The specificity of the primers and probes was evalu-
ated using BLAST analysis, and analyzing nucleic acid 
from various bacterial and viral strains in the multiplex 
real-time PCR (Additional file 1, Table S1). In silico and 
in vitro analyses revealed that the M. pneumoniae prim-
ers and probe designed for detection of the most com-
mon resistance-associated mutations could also amplify 
DNA from Mycoplasma genitalium.
Diagnostic performance of the multiplex PCR
To evaluate the reliability of the developed real-time 
multiplex PCR for clinical testing the performance of 
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the assay was compared to those of the reference PCR 
assays. A total of 42  M. pneumoniae positive speci-
mens and 24  M. pneumoniae simulated BALs were 
studied with the multiplex assay. The multiplex real-
time PCR detected all simulated BALs correctly and 
the assay was in 100  % agreement with the reference 
PCRs (Table 1).
The macrolide resistance-associated mutations in M. 
pneumoniae strains were identified by dissociation curve 
analysis of the amplicon. The analysis distinguishes muta-
tions in 23S rRNA sequence at positions 2063G/C or 
2064G/C. The melting temperature of the wild type is 
64–65 °C, for the mutation C 60–61 °C and for the muta-
tion G 57.5–58.5 °C (Fig. 1). The dissociation curve analy-
sis does not differentiate whether the mutation is in the 
base 2063 or 2064. In our study material, 9.5 % (4/42) of 
the M. pneumoniae positive specimens contained a M. 
pneumoniae strain with macrolide resistance-associated 
mutation. The PCR results were confirmed by sequence 
analysis. Two BALs and two sputum specimens con-
tained M. pneumoniae with a mutation associated with 
macrolide resistance. Three M. pneumoniae strains had a 
point mutation at 2063 A->G and one sputum specimen 
contained both wild type DNA and DNA with a point 
mutation at 2064 A->G.
The C. pneumoniae component in the multiplex PCR 
uses same oligonucleotides as the previously validated 
reference PCR and hence the performance of the C. 
pneumoniae component was verified with a smaller 
amount of specimens. The clinical sensitivity was veri-
fied by testing 28 C. pneumoniae positive or simulated 
positive upper and lower respiratory tract specimens. In 
addition, a total of 43 C. pneumoniae negative respira-
tory tract specimens were assessed. The multiplex PCR 
assay was in 100 % agreement with the reference method 
(Table 1).
External quality assessment panel
EQA panel C. pneumoniae and M. pneumoniae 2014 
(QCMD, Glasgow, Scotland, UK) was analyzed with the 
multiplex real-time PCR assay. The multiplex PCR iden-
tified all core proficiency samples correctly. Only two 
educational, infrequently detected M. pneumoniae posi-
tive specimens were not detected by the multiplex PCR 
(CP.MP14-03 and CP.MP14-12) and one educational 
infrequently detected C. pneumoniae positive specimen 
CP.MP14-06 gave a negative result (Table 2).
Discussion
Mycoplasma pneumoniae and C. pneumoniae cause atyp-
ical pneumonia and have clinically similar respiratory 
manifestations. Hence it is logical to detect them simul-
taneously. To improve laboratory diagnosis and to reduce 
the cost and time for detecting M. pneumoniae and C. 
pneumoniae, we designed and validated a multiplex real-
time PCR that can also detect the most common muta-
tions in the 23S rRNA gene of M. pneumoniae leading to 
macrolide resistance in a single reaction. Human beta-
globin gene was included as an internal control to allow 
assessment of the specimen quality and the nucleic acid 
extraction as well as the amplification processes. No inhi-
bition or specimen processing errors were identified in 
this study. The variation of the detected IC Ct values for 
swab specimens and BAL specimens follows normal dis-
tribution (mean and median are almost identical) and is 
therefore more likely to reflect variation in the sampling 
procedure.
All specimens were analysed both in singleplex and in 
multiplex reactions. Multiplex PCR may lack sensitiv-
ity when compared to singleplex PCR (Mannonen et al. 
2012), but here the carefully optimized multiplex PCR 
had identical sensitivity in comparison to the singleplex 
PCR (data not shown). The obtained LOD 2.9 cp/reac-
tion for M. pneumoniae can be considered functional and 
is comparable to those reported by others (Dumke and 
Jacobs 2009, 2014; Welti et al. 2003; Schmitt et al. 2013). 
For the C. pneumoniae component of the multiplex 
PCR, the LOD of 0.13 IFU/PCR reaction was obtained. 
The sensitivities of previously published PCR assays are 
challenging to compare since no standard preparations 
for measuring analytical sensitivity are available (Dow-
ell et  al. 2001). Until international molecular standards 
become available, molecular EQA panels may be the best 
way to estimate sensitivity of a molecular test. Here we 
analysed a QCMD 2014 proficiency panel for C. pneumo-
niae and M. pneumoniae with the developed multiplex 
PCR method. The multiplex PCR method identified all 
core samples correctly indicating acceptable level of pro-
ficiency. In addition, 3/6 educational samples were iden-
tified correctly. The remaining three educational samples 
Table 1 Comparison of  the results from  multiplex real-
time PCR and reference PCRs for detection of (a) M. pneu-
moniae (MP) and (b) C. pneumoniae (CP) in clinical respira-
tory specimens
M. pneumoniae  
(MP)
Reference PCRs Total
MP pos MP neg
Multiplex PCR  MP pos 42 0 42
 MP neg 0 43 43
 Total 42 43 85
C. pneumoniae (CP) CP pos CP neg Total
Multiplex PCR  CP pos 28 0 28
 CP neg 0 43 43
 Total 28 43 71
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Fig. 1 Melting curve displaying a patient sample containing DNA from M. pneumoniae with macrolide resistance-associated mutation (MR–MP). 
The melting profile of a patient sample was compared to the melting profiles of 3 controls: (1) Plasmid control 2063C which contains M. pneumoniae 
23S rRNA PCR target sequence with base C at the position 2063 (DNA amplicon with base C at the position 2064 displays similar melting profile, 
data not shown). (2) Plasmid control 2063G which contains M. pneumoniae 23S rRNA target sequence with base G at the position 2063 (DNA ampli-
con with base G at position the 2064 displays similar melting profile, data not shown). (3) Wt (wild type) M. pneumoniae DNA
Table 2 The results of QCMD 2014 proficiency panel for C. pneumoniae and M. pneumoniae using the developed multi-
plex PCR method
BAL Bronchoalveolar lavage, TM transport medium, Core sample type that all participants are expected to detect correctly, Educational sample type that is designed to 
provide educational information to participants
Sample Matrix Sample content Result with the 
multiplex‑PCR
Sample status/percentage of laboratories 
that reported positive result for the  
pathogen in question
Sample type
CP.MP14-01 BAL C. pneumoniae C. pneumoniae Frequently detected/96.2 % Core
CP.MP14-02 TM M. pneumoniae M. pneumoniae Detected/73.9 % Educational
CP.MP14-03 TM M. pneumoniae Negative Infrequently detected/20.6 % Educational
CP.MP14-04 TM Negative Negative Negative Core
CP.MP14-05 TM C. pneumoniae C. pneumoniae Frequently detected/98.4 % Core
CP.MP14-06 TM C. pneumoniae Negative Infrequently detected/58 % Educational
CP.MP14-07 BAL Negative Negative Negative Core
CP.MP14-08 BAL M. pneumoniae M. pneumoniae Detected/78.4 % Educational
CP.MP14-09 TM C. pneumoniae C. pneumoniae Detected/82.5 % Educational
CP.MP14-10 BAL C. pneumoniae C. pneumoniae Frequently detected/98.4 % Core
CP.MP14-11 TM M. pneumoniae M. pneumoniae Detected/94.5 % Core
CP.MP14-12 BAL M. pneumoniae Negative Infrequently detected/43.7 % Educational
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which tested negative by the multiplex PCR and the ref-
erence methods, were infrequently detected by the pro-
ficiency panel participants, and only 20.6 and 43.7  % of 
the laboratories reported positive M. pneumoniae results 
and 58  % positive C. pneumoniae result for these sam-
ples indicating very low level of bacteria in these samples. 
Overall, the developed multiplex real-time PCR showed 
good specificity and sensitivity for detecting M. pneumo-
niae and C. pneumoniae in clinical and simulated speci-
mens. The performance of the multiplex PCR assay was 
comparable to that of the reference PCRs.
Macrolides are considered the treatment of choice for 
M. pneumoniae infections. Since 2000, M. pneumoniae 
strains resistant to macrolides have emerged (Bébéar 
et al. 2011; Principi and Esposito 2013). Mutations in the 
23S rRNA gene can confer resistance to macrolides and 
the most commonly occurring mutations are A2063G 
and A2064G. In our study, 9.5  % of M. pneumoniae 
strains were shown to have either of these mutations. The 
observed rate is similar to those reported in other Euro-
pean countries and USA (0–26 %), whereas in Japan and 
China, the occurrence of macrolide resistance is much 
higher (>90 %) (Bébéar et al. 2011; Principi and Esposito 
2013). A2063G is the most commonly detected muta-
tion worldwide (>90 % of all reported point mutations), 
and this was also the case in our study (three out of four 
cases had A2063G mutation). In silico and in vitro stud-
ies revealed that the primers and the probe for macrolide 
resistance mutations also detected M. genitalium. The 
23S rRNA genes of M. pneumoniae and M. genitalium 
are closely related (96.7  % identity) and therefore the 
observed cross-reactivity is not surprising (Dumke et al. 
2010). M. genitalium, however, is not frequently detected 
in respiratory specimens. Moreover, the presence of M. 
pneumoniae is first identified by specific oligonucleotides 
and the presence of mutation is evaluated only in M. 
pneumoniae positive specimens, so the risk of incorrect 
identification was considered minimal.
As antimicrobial therapy effective against M. pneu-
moniae and C. pneumoniae infections is available and 
recommended in lower respiratory tract infections, 
molecular testing can aid in patient management by pro-
viding a microbiological diagnosis and guiding antibiotic 
selection. Sensitive nucleic acid based detection tech-
niques also contribute to a better understanding of the 
epidemiology and manifestations of these infections.
Conclusions
We have developed a resources conserving multiplex 
real-time PCR assay which has been successfully imple-
mented in a clinical diagnostic laboratory for simultane-
ous detection of M. pneumoniae, C. pneumoniae and the 
most common mutations leading to macrolide resistance 
in M. pneumoniae. The assay is a widely useful tool for 
detection of these respiratory pathogens and will also 
shed light on the occurrence of macrolide resistance in 
M. pneumoniae.
Methods
Design of primers and probes
Primer Express software v 3.0 (Applied Biosystems, Fos-
ter City, CA) was used to design primers and probes tar-
geting a conserved hypothetical protein C985_0367 of M. 
pneumoniae (MP) (MP M129-B7) and human β-globin 
(BG) gene. The C. pneumoniae (CP) primers and probe 
have previously been described by Mannonen et al. 2004. 
The primers and probe for detection of macrolide resist-
ance-associated mutations in M. pneumoniae (MR–MP) 
were designed by TIB MOLBIOL (Berlin, Germany). All 
primers and probes were tested for specificity by basic 
local alignment search tool (BLAST). The primer and 
probe sequences are listed in Table 3.
Multiplex real‑time PCR design
Endogenous IC human β-globin PCR assay was opti-
mized as a primer limited reaction to avoid competition 
between other amplifications. The multiplex PCR reac-
tion consisted of 5  µl of extracted DNA, 1  ×  Maxima 
Probe qPCR Master Mix (Thermo Scientific) 0.05  µM 
CP-Fw, 0.2  µM CP-Rev, 0.175  µM CP-probe, 0.250  µM 
MP-Fw and MP-Rev primers, 0.150 µ MP-probe, 0.05 µM 
MR-MP-Fw, 0.400  µM MR-Mp-Rev, 0.150 MR-MP-
probe, 0.05  µM BG-Fw, 0.1  µM BG-Rev, 0.05  µM BG-
probe and nuclease-free water in a total reaction volume 
of 25 μl.
Multiplex PCRs were performed using Stratagene 
Mx3005p instrument (Agilent Technologies Inc, Santa 
Clara, CA, United States). Positive and negative controls 
as well as a no template control (NTC) were included 
in each run. Cycling conditions were 1 cycle 95  °C for 
10 min followed by 45 cycles of 95 °C for 15 s and 60 °C 
for 60  s. After amplification a dissociation curve analy-
sis was performed with a thermal profile: 95 °C for 60 s, 
55 °C for 30 s followed by a slow rise in the temperature 
(0.2 °C/s) to 95 °C with continuous acquisition of fluores-
cence signal.
Reference PCRs
The M. pneumoniae results by the new multiplex PCR 
were compared to those obtained by the diagnostic M. 
pneumoniae PCR test in use at the time of the study at 
HUSLAB (adapted from van Kuppeveld et al. 1992) or to 
M. pneumoniae PCR targeting CARDS toxin (CARDStx) 
gene adapted from Winchell et al. 2008. For the diagnos-
tic PCR, 5  µl of nucleic acid extract was amplified in a 
50 µl reaction volume with 0.5 µM of primers (Table 3). 
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Amplified products were detected by microplate hybridi-
zation (Vesanen et al. 1996). PCR products were detected 
with digoxigenin labelled probe (Table  3), anti-digoxi-
genin antibody conjugated with alkaline phosphatase and 
LumiPhos Plus substrate (Lumigen, Souhfield, MI, USA). 
For the CARDStx PCR 5  µl of nucleic acid extract was 
amplified in 25 µl PCR reaction with 0.25 µM of primers 
and 0.125 µM probe (Table 3). The real-time PCR reac-
tion was carried out in Stratagene Mx3005p instrument.
The C. pneumoniae results obtained by the new mul-
tiplex PCR were compared to those of the diagnostic C. 
pneumoniae PCR test in use at the time of the study at 
HUSLAB (Mannonen et al. 2004) (with minor modifica-
tions). The primers and probe were the same as in the 
new multiplex test. Five µl of nucleic acid extract was 
amplified in 50 µl reaction mixture with 0.3 µM forward 
and reverse primer and 0.225 µM probe (Table 3).
Specimens
Respiratory tract specimens referred to HUSLAB, 
Department of Virology and Immunology for testing 
of M. pneumoniae, C. pneumoniae and/or respiratory 
viruses between years 1999–2014, were analyzed in this 
study. The specimens included 42  M. pneumoniae posi-
tive specimens assessed by diagnostic PCR of that time 
(29) (van Kuppeveld et  al. 1992) or by CARDS Tx PCR 
(13) (Winchell et  al. 2008). The specimens were naso-
pharyngeal swabs (24), nasopharyngeal aspirates (5), 
sputum samples (6), tracheal aspirates (5) and bronchoal-
veolar lavages (BAL; 2). Due to the limited amount of M. 
pneumoniae positive BAL specimens, 24 negative BALs 
were spiked with M. pneumoniae positive respiratory 
specimens in dilutions 1:10–1:1000.
The C. pneumoniae positive specimens included two 
sputum samples and three nose and/or throat swabs, 12 
simulated BALs and 11 simulated respiratory tract speci-
mens. The simulated specimens were prepared by spik-
ing negative BALs and respiratory tract specimens with 
C. pneumoniae strain K6 yielding 1.25 inclusion form-
ing unit (IFU)/PCR reaction or 250 IFU/PCR reaction. 
Altogether 43 M. pneumoniae and C. pneumoniae nega-
tive upper and lower respiratory tract specimens were 
Table 3 Primer and probe sequences for amplification of C. pneumoniae, M. pneumoniae, macrolide resistance associated 
mutations in  M. pneumoniae and  human beta-globin DNA, as  well as  the primer sequences used for  sequencing of  M. 
pneumoniae 23S rRNA
a Dually labelled hydrolysis probe
b Sequencing primer
Primer/probe Sequence 5′‑>3′ Gene target (reference)
MP Fw ATGTACTATCAGCAAAAGCTCAGTATGG M. pneumoniae Hyppthetical protein C985_0367
(GeneBank accesion no: AGC04275.1)
(this publication)
MP Rev CCACATACCGCTTTAAGTTAGCAA
MP probea Cy5-CTAACCAAAACAGCCCTTCAACGGCA-Iowa black 
RQ-Sp
CP Fw AAGGGCTATAAAGGCGTTGCT C. pneumoniae ompA
(Mannonen et al. 2004)CP Rev TGGTCGCAGACTTTGTTCCA
CP probea Tx Red-TCCCCTTGCCAACAGACGCTGG-Iowa black 
RQ-Sp
BG Fw GGTTGGGATAAGGCTGGATTATT Homo sapiens beta-globin chain
(GeneBank accesion no: AY260740.1)
(this publication)
BG Rev CAGGAGCTGTGGGAGGAAGA
BG probea JOE/ZEN-CAAGCTAGGCCCTTTTGCTAATCATGTTCA- 
Iowa black FQ
MR–MP Fw GCTATAGACTCGGTGAAATCCAGG M. pneumoniae gene for 23S rRNA (GeneBank accesion 
no: gi|288509|emb|X68422.1|)
(this publication)
MR–MP Rev GCTACAGTAAAGCTTCACTGGGTC
MR–MP SimpleProbe® GCGCA XI ACGGGACGGAAAGAC
CARDS TX Fw TTTGGTAGCTGGTTACGGGAAT CARDS toxin gene
(Winchell et al. 2008)CARDS TX Rev GGTCGGCACGAATTTCATATAAG
CARDS TX probea TGTACCAGAGCACCCCAGAAGGGCT
M. pneumoniae Fw diagnostic PCR AAGGACCTGCAAGGGTTCGT 16SrRNA
(van Kuppeveld et al. 1992)M. pneumoniae Rev diagnostic PCR Biotin-CTCTAGCCATTACCTGCTAA
M. pneumoniae probe diagnostic PCR ACTCCTACGGGAGGCAGCAGTA-digoxigenin
MR Seq Fwb AACTATAACGGTCCTAAGGTAGCG 23srRNA
(Wolff et al. 2008)MR Seq Revb GCTCCTACCTATTCTCTACATGAT
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assessed in this study. In addition, the QCMDs External 
Quality assurance panel 2014 Chlamydophila pneumo-
niae and Mycoplasma pneumoniae was used to evaluate 
the performance of the developed multiplex real-time 
PCR.
DNA extraction
DNA was extracted from respiratory specimens using 
MagNA Pure LC Total Nucleic Acid Isolation Kit or 
MagNA Pure DNA/Viral NA SV 2.0 Kit (Roche Diag-
nostics GmbH, Mannheim, Germany). In detail, 300 µl 
of specimen was lysed with 300  µl of MagNA Pure 
Lysis/Binding Buffer (Roche Diagnostics GmbH, Man-
nheim, Germany). Five hundred µl (MagNA Pure LC) 
or 450  µl (MagNA Pure 96) of specimen lysate was 
extracted with the MagNA Pure LC or the MagNA 
Pure 96-instrument and eluted in 50  µl of the elution 
buffer.
Specimens tested by the reference M. pneumoniae 
and C. pneumoniae PCRs had been extracted by either 
using MagNA Pure LC, EasyMAG instrument (bioMer-
ieux, Marcy l’Etoile, France) or phenol–chloroform 
extraction. Starting volumes were 1800  µl for BALs, 
200  µl for nasopharyngeal aspirates and sputum speci-
mens, and 100  µl for nasopharyngeal swabs. Nucleic 
acids extracted by EasyMAG were eluted in 25  µl and 
those extracted by phenol–chloroform protocol were 
eluted either in 50  µl (nasopharyngeal swabs) or 20  µl 
(other specimens).
Sequencing analysis of PCR products
Nucleotide sequence analysis of M. pneumoniae 23S 
rRNA gene (GeneBank. X68422) was performed to 
all specimens containing mutations associated with 
macrolide resistance in M. pneumoniae according to 
the developed multiplex real-time PCR. The primer 
sequences have been previously described (Table 3). The 
PCR products were sequenced in the Institute of Bio-
technology at the University of Helsinki.
Analytical sensitivity
The analytical sensitivity of the multiplex real-time PCR 
assay was assessed by amplifying serial dilutions of M. 
pneumoniae M129 DNA control (ZeptoMetrix Corpo-
ration, Franklin, MA) and DNA from C. pneumoniae 
K-6 (quantitated at Mirja Puolakkainen’s research labo-
ratory). Four dilutions with ten replicates of each were 
amplified with the multiplex real-time PCR carried out 
in Mx3005p instrument. The tested M. pneumoniae M 
129 DNA dilutions were 6.210, 3.105, 1.552 and 0.776 
genome copies (cp)/PCR reaction, and C. pneumoniae 
K-6 DNA dilutions were 0.250, 0.125, 0.063 and 0.032 
IFU/PCR reaction.
Analytical specificity
To assess the analytical specificity of the multiplex PCR 
assay various bacterial and viral samples were studied 
(Additional file 1, Table S1).
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